[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334706-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334706-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","heterogeneity-of-primary-and-metastatic-cafs-from-differential-treatment-outcomes-to-treatment-opportunities-review","Heterogeneity of primary and metastatic CAFs - From differential treatment outcomes to treatment opportunities - Review","","Metastatic tumor sites often show greater resistance to therapy and respond differently from primary tumor locations, indicating a treatment-context dependence. This review attributes the divergence to heterogeneity in the tumor microenvironment between metastatic and primary sites, particularly involving cancer-associated fibroblast subtypes. It outlines how differences in CAF source, activation mode, markers, and functional phenotypes can shape local micro-landscapes, influencing drug sensitivity and ultimately guiding treatment opportunities.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/heterogeneity-of-primary-and-metastatic-cafs-from-differential-treatment-outcomes-to-treatment-opportunities-review/334706/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/heterogeneity-of-primary-and-metastatic-cafs-from-differential-treatment-outcomes-to-treatment-opportunities-review/334706.png","ImageObject",300,407,{"name":42,"@type":43},"Ava Thompson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why do metastatic sites respond differently from primary tumor sites to treatment?","Question",{"text":63,"@type":64},"Metastatic sites tend to be more resistant and show different responses, which is linked to heterogeneity in the tumor microenvironment between metastatic and primary locations.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What does the review describe about primary and metastatic CAFs?",{"text":68,"@type":64},"Primary CAFs (pCAFs) and metastatic CAFs (mCAFs) are heterogeneous in their source, activation modes, markers, and functional phenotypes.",{"name":70,"@type":61,"acceptedAnswer":71},"How can understanding pCAFs and mCAFs improve treatment opportunities?",{"text":72,"@type":64},"By revealing differences in treatment outcomes mediated by CAF heterogeneity, the review suggests new ideas for improving control of metastasis across cancers and identifying therapeutic opportunities targeting mCAFs.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334706,1790356507,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","INTERNATIONAL JOURNAL OF ONCOLOGY 64: 54, 2024  \nHeterogeneity of primary and metastatic CAFs: From differential treatment outcomes to treatment opportunities (Review)  \nZIXING KOU 1* , CUN LIU2* , WENFENG ZHANG3 , CHANGGANG SUN2,4 , LIJUAN LIU4 and QIMING ZHANG 1,5  \n1College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355; 2College of Traditional Chinese Medicine, Shandong Second Medical University, Weifang, Shandong 261053; 3State Key Laboratory of Quality Research in Chinese Medicine and Faculty of Chinese Medicine, Macau University of Science and Technology, Taipa Island 999078, Macau SAR; 4Department of Oncology, Weifang Traditional Chinese Hospital, Weifang, Shandong 621000; 5Department of Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100007, P.R. China  \nReceived November 9, 2023; Accepted March 13, 2024  \nDOI: 10.3892/ijo.2024.5642  \nAbstract. Compared with primary tumor sites, metastatic sites appear more resistant to treatments and respond differently to the treatment regimen. It may be due to the heterogeneity in the microenvironment between metastatic sites and primary  \nCorrespondence to: Professor Lijuan Liu, Department of Oncology, Weifang Traditional Chinese Hospital, 11166 Baotong East Road, Kuiwen, Weifang, Shandong 621000, P.R. China  \nE‑[mail: hxdhxd19852003@163.com](mail: hxdhxd19852003@163.com)  \nProfessor Qiming Zhang, Department of Experimental Research Center, China Academy of Chinese Medical Sciences, 16 Nanxiao Street, Dongzhimen, Dongcheng, Beijing 100007, P.R. China  \nE‑mail: [zhang_917@126.com](zhang_917@126.com)  \n*Contributed equally  \nAbbreviations: CAFs, cancer‑associated fibroblasts; mCAFs, metastatic CAFs; pCAFs, primary CAFs; RFs, resident fibroblasts; ECM, the extracellular matrix; MSCs, mesenchymal stem cells; BM‑MSCs, bone marrow‑derived MSCs; NFs, Normal fibroblasts; PSCs, pancreatic stellate cells; HSCs, hepatic stellate cells; LMs, liver metastases; myCAFs, myofibroblastic CAFs; iCAFs, inflammatory CAFs; PFs, portal fibroblasts; apCAFs, antigen‑presenting CAFs; scRNA‑seq, single‑cell RNA sequencing; αSMA, smooth muscle actin‑α; TGF‑β, transforming growth factor‑β; Met‑LNs, lymph node metastasis; EMT, epithelial‑mesenchymal transition; FSP1, fibroblast‑specific protein 1; FAP, fibroblast activation protein; FAPi, FAP inhibitor; PDGF, platelet‑derived growth factor; PDGFR, PDGF receptor; SDF‑1, stromal cell‑derived factor 1; OPN, osteopontin; COL, collagen; CXCR, C‑X‑C chemokine receptor; IL, interleukin; SUVs, standardized uptake values; LRG1, leucine‑rich ɑ‑2‑glycoprotein 1; SAM, S‑adenosyl methionine; LOX, lysyl oxidases; HA, hyaluronan  \nKey words: metastatic cancer‑associated fibroblast, primary cancer‑ associated fibroblast, heterogeneity, tumor microenvironment, treatment outcomes, treatment opportunities  \ntumors . Cancer‑associated fibroblasts (CAFs) are widely present in the tumor stroma as key components of the tumor microenvironment . Primary tumor CAFs (pCAFs) and metastatic CAFs (mCAFs) are heterogeneous in terms of source, activation mode, markers and functional phenotypes. They can shape the tumor microenvironment according to organ, showing heterogeneity between primary tumors and metastases, which may affect the sensitivity of these sites to treatment. It was hypothesized that understanding the hetero‑ geneity between pCAFs and mCAFs can provide a glimpse into the difference in treatment outcomes, providing new ideas for improving the rate of metastasis control in various cancers.  \nContents  \n1. Introduction  \n2. Heterogeneity of mCAFs and pCAFs  \n3. Differential therapeutic response mediated by pCAFs and mCAFs  \n4. Potential therapeutic opportunities targeting mCAFs  \n5. Conclusion  \n1. Introduction  \nThe simultaneous treatment of both primary and metastatic tumors is the main treatment option following tumor metas‑ tasis. However, the treatment for the primary tumor often has","cbCaiq8jVu9QD9jw","https://ap.wps.com/l/cbCaiq8jVu9QD9jw","pdf",3022013,"English","# Contents\n## Introduction\n## Heterogeneity of mCAFs and pCAFs\n## Differential therapeutic response mediated by pCAFs and mCAFs\n## Potential therapeutic opportunities targeting mCAFs\n## Conclusion","[{\"question\":\"Why do metastatic sites respond differently from primary tumor sites to treatment?\",\"answer\":\"Metastatic sites tend to be more resistant and show different responses, which is linked to heterogeneity in the tumor microenvironment between metastatic and primary locations.\"},{\"question\":\"What does the review describe about primary and metastatic CAFs?\",\"answer\":\"Primary CAFs (pCAFs) and metastatic CAFs (mCAFs) are heterogeneous in their source, activation modes, markers, and functional phenotypes.\"},{\"question\":\"How can understanding pCAFs and mCAFs improve treatment opportunities?\",\"answer\":\"By revealing differences in treatment outcomes mediated by CAF heterogeneity, the review suggests new ideas for improving control of metastasis across cancers and identifying therapeutic opportunities targeting mCAFs.\"}]","Heterogeneity of primary and metastatic CAFs - From differential treatment outcomes to treatment opportunities - Review | PDF",1790007964,76]